FEATURE: With the Market in the Dumps, VCs Rethink Genomics Valuations | GenomeWeb

NEW YORK, March 30 – Executives at early-stage genomics companies seeking startup capital will have to reduce their expectations regarding the valuations they can expect to command for their companies, given the sharp downturn in the stock markets, venture capitalists said Friday. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.